


PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5432810

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	AGNETE B. FREDRIKSEN	05/19/2017
RECEIVING PARTY DATA		
Name:	VACCIBODY AS	
Street Address:	GAUSTADALLEEN 21	
City:	OSLO	
State/Country:	NORWAY	
Postal Code:	0349	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16312337
CORRESPONDENCE DATA		
Fax Number:	(608)662-1276	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	macheckett@casimirjones.com	
Correspondent Name:	J. MITCHELL JONES	
Address Line 1:	CASIMIR JONES, S.C.	
Address Line 2:	2275 DEMING WAY, STE 310	
Address Line 4:	MIDDLETON, WISCONSIN 53562	
ATTORNEY DOCKET NUMBER:	INVEN-34866/US-2/PCT	
NAME OF SUBMITTER:	J. MITCHELL JONES	
SIGNATURE:	/J. Mitchell Jones/	
DATE SIGNED:	03/21/2019	
Total Attachments: 2		
source=34866US1PRO_Assignment_Vaccibody_EXEC#page1.tif		
source=34866US1PRO_Assignment_Vaccibody_EXEC#page2.tif		



ASSIGNMENT OF INVENTIONS AND IP ASSETS

This ASSIGNMENT OF INVENTIONS AND IP ASSETS ("Assignment"), dated 12 May 2017 (the "Effective Date"), is entered into by Agnete Brunsvik Fredriksen, Strandvegen 5A, 2005 Rælingen, Norway ("Assignor"), for the benefit of Vaccibody AS, a Norwegian corporation having its place of business at Gaustadalléen 21, N-0349, Oslo and its successors and assigns ("Assignee").

WHEREAS Assignor, as a result of services performed by her in connection with her employment as Chief Scientific Officer for Assignee, has made an invention as described in the US Provisional Patent Application Serial No. 62/352,815, filed 21 June 2016 ("Invention").

WHEREAS Assignee, in accordance with § 6 of the Norwegian Employee's Invention Act (Norsk lov om retten til oppfinnelser som er gjort av arbeidstakere), has claimed the Invention for Assignee on 12 May 2017.

WHEREAS Assignor and Assignee want to formalize this transfer of rights by entering into this Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Assignor hereby transfers, assigns, conveys and delivers to Assignee all right, title and interest she has or may acquire in and to the Invention and the IP Assets (defined below) and all benefits and/or rights resulting therefrom to the Assignee without further compensation.

As used herein "IP Assets" means all proprietary rights in the Invention, including, without limitation, all patentable subject matter, all resulting priority, international and ordinary national patent applications or nationalized international applications, all patents granted for such patent applications, all priority rights, all copyright and trade secret rights, and all technical information, documents, data, designs, know-how, show-how, prototypes, software, trade secrets and other proprietary information relating to, claiming or covering the Invention; all rights to commercialize the Invention; and all benefits and/or rights resulting therefrom.

Assignor shall, at the request and cost of Assignee, promptly sign, execute, make and do all such deeds, documents, acts, transfers, assignments, conveyances, powers of attorney, assurances and things as Assignee and its duly authorized officers may reasonably require to better assure, convey and confirm unto Assignee or its successor and assigns my entire right, title and interest in the Invention and the IP Assets.

Assignor's obligations under this Assignment shall be binding upon its successors, executors, administrators and legal representatives, and will inure to the benefit of Assignee, its successors and assigns. Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, corporation or entity other than Assignee, its successors and assigns, any remedy or claim under or by reason of this instrument, or any terms, covenants or conditions hereof, and all the terms, covenants and conditions in this instrument shall be for the sole and exclusive benefit of Assignee and its successors and assigns.

IN WITNESS WHEREOF, this Assignment was executed as of the date written below.

Assignor

Place and date:

Oslø, May 19, 2017

Signature:

Agnete Brunsvik Fredriksen
Agnete Brunsvik Fredriksen, Chief Scientific Officer

Assignee

Place and date:

Oslø, May 16, 2017

Name/title:

Martin Bonde, Chief Executive Officer

Signature:

Vaccibody A/S